August 14, 2024 01:31 AM EDTUpdated 06:37 AM
Diagnostics

To get back to growth, Il­lu­mi­na CEO says it's sim­pli­fy­ing DNA se­quenc­ing and analy­sis

Jared Whitlock

Features Editor

On Tues­day, Il­lu­mi­na laid out a three-year plan for in­vestors de­tail­ing how the strug­gling DNA se­quenc­ing com­pa­ny plans to get back to growth. To do …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times